Total Valuation
AgomAb Therapeutics NV ADR has a market cap or net worth of $643.18M. The enterprise value is $242.33.
Market Cap$643.18M
Enterprise Value$242.33
Share Statistics
AgomAb Therapeutics NV ADR has 49,247,974 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding49,247,974
Owned by Insiders―
Owned by Institutions44.55%
Financial Efficiency
AgomAb Therapeutics NV ADR’s return on equity (ROE) is -0.48 and return on invested capital (ROIC) is -43.79%.
Return on Equity (ROE)-0.48
Return on Assets (ROA)-0.41
Return on Invested Capital (ROIC)-43.79%
Return on Capital Employed (ROCE)-0.44
Revenue Per Employee0.00
Profits Per Employee-1.01M
Employee Count62
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of AgomAb Therapeutics NV ADR is ―. AgomAb Therapeutics NV ADR’s PEG ratio is -6.14.
PE Ratio―
PS Ratio0.00
PB Ratio4.64
Price to Fair Value4.64
Price to FCF-11.74
Price to Operating Cash Flow-19.33
PEG Ratio-6.14
Income Statement
In the last 12 months, AgomAb Therapeutics NV ADR had revenue of 0.00 and earned -62.55M in profits. Earnings per share was -1.28.
Revenue0.00
Gross Profit0.00
Operating Income-59.27M
Pretax Income-62.55M
Net Income-62.55M
EBITDA-62.27M
Earnings Per Share (EPS)-1.28
Cash Flow
In the last 12 months, operating cash flow was -26.81M and capital expenditures -4.00K, giving a free cash flow of -26.81M billion.
Operating Cash Flow-26.81M
Free Cash Flow-26.81M
Free Cash Flow per Share-0.54
Dividends & Yields
AgomAb Therapeutics NV ADR pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.56
52-Week Price Change-10.85%
50-Day Moving Average13.38
200-Day Moving Average―
Relative Strength Index (RSI)44.74
Average Volume (3m)145.91K
Important Dates
AgomAb Therapeutics NV ADR upcoming earnings date is Aug 6, 2026, After Close (Confirmed).
Last Earnings DateApr 23, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
AgomAb Therapeutics NV ADR as a current ratio of 6.52, with Debt / Equity ratio of 0.43%
Current Ratio6.52
Quick Ratio6.52
Debt to Market Cap0.00
Net Debt to EBITDA1.37
Interest Coverage Ratio-987.92
Taxes
In the past 12 months, AgomAb Therapeutics NV ADR has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
AgomAb Therapeutics NV ADR EV to EBITDA ratio is -8.39, with an EV/FCF ratio of -10.10.
EV to Sales0.00
EV to EBITDA-8.39
EV to Free Cash Flow-10.10
EV to Operating Cash Flow-10.10
Balance Sheet
AgomAb Therapeutics NV ADR has $116.51M in cash and marketable securities with $1.25M in debt, giving a net cash position of $115.26M billion.
Cash & Marketable Securities$116.51M
Total Debt$1.25M
Net Cash$115.26M
Net Cash Per Share$2.34
Tangible Book Value Per Share$1.99
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for AgomAb Therapeutics NV ADR is $34.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$34.80
Price Target Upside120.53% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast―